Blood group genotyping

Revista Brasileira de Hematologia e Hemoterapia

Lilian Castilho¹  Jordão Pellegrino Júnior¹ 

[1] ,Unicamp Hemocentro

关键词: Blood group antigens;    DNA technology;    transfused patients;    hemagglutination;    maternal-fetal medicine;    Antígenos de grupos sangüíneos;    DNA;    hemaglutinação;    medicina transfusional;    medicina materno-fetal;   

DOI  :  10.1590/S1516-84842004000200012

来源: SciELO

【 摘 要 】

Accurate phenotyping of red blood cells (RBCs) can be difficult in transfusion-dependent patients such as those with thalassemia and sickle cells anemia because of the presence of previously transfused RBCs in the patient's circulation. Recently, the molecular basis associated with the expression of many blood group antigens was established. This allowed the development of a plethora of polymerase chain reaction-based tests for identification of the blood group antigens by testing DNA. The determination of blood group polymorphism at the genomic level facilitates the resolution of clinical problems that cannot be addressed by hemagglutination. They are useful to (a) determine antigen types for which currently available antibodies are weakly reactive; (b) type patients who have been recently transfused; (c) identify fetuses at risk for hemolytic disease of the newborn; and (d) to increase the reliability of repositories of antigen negative RBCs for transfusion. It is important to note that PCR based assays are prone to different types of errors that those observed with hemagglutination assays. For instance, contamination with amplified products may lead to false positive test results. In addition, the identification of a particular genotype does not necessarily mean that the antigen will be expressed on the RBC membrane.

【 授权许可】

CC BY-NC-ND   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License